Company news
Kura Oncology, Inc. news in 2024
Kura Oncology, Inc.'s news releases, calls and decks from 2024, newest first.
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
December 8, 2024
Kura Oncology to Host Virtual Investor Event on December 9, 2024
December 1, 2024
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
November 24, 2024
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
November 19, 2024
Kura Oncology Reports Third Quarter 2024 Financial Results
November 6, 2024
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
November 4, 2024
Kura Oncology to Report Third Quarter 2024 Financial Results
October 30, 2024
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
October 23, 2024
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
October 22, 2024
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
September 29, 2024
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
September 16, 2024
Kura Oncology to Participate in Cantor Global Healthcare Conference
September 9, 2024
Kura Oncology Reports Second Quarter 2024 Financial Results
August 7, 2024
Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)
August 7, 2024
Kura Oncology to Report Second Quarter 2024 Financial Results
July 31, 2024
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
June 23, 2024
Kura Oncology to Participate in Jefferies Global Healthcare Conference
May 28, 2024
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
May 13, 2024
Kura Oncology Reports First Quarter 2024 Financial Results
May 1, 2024
Kura Oncology to Report First Quarter 2024 Financial Results
April 24, 2024
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
April 21, 2024
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
March 5, 2024
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
February 26, 2024
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
February 25, 2024
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
February 19, 2024
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
January 29, 2024
Kura Oncology Announces Oversubscribed $150 Million Private Placement
January 23, 2024
Calls in 2024
Decks in 2024
- Technical Presentation (December 2024)
Technical · 15 slides · December 2024
- Q3 2024 Earnings Presentation
Earnings · 49 slides · Nov 7, 2024
- Q2 2024 Earnings Presentation
Earnings · 42 slides · Aug 8, 2024
- Technical Presentation (June 2024)
Technical · 10 slides · Jun 21, 2024
- Q1 2024 Earnings Presentation
Earnings · 37 slides · May 2, 2024
- Q4 2023 Earnings Presentation
Earnings · 36 slides · Feb 27, 2024
- Technical Presentation (January 2024)
Technical · 31 slides · Jan 30, 2024
- CTOS 2024 Annual Meeting
Conference · 22 slides · 2024